title: Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.
authors.affiliation: Santa Maria della Misericordia Hospital, Perugia, Italy.
authors.forename: Rita
authors.initials: R
authors.lastname: Chiari
authors.forename: Simona
authors.initials: S
authors.lastname: Duranti
authors.forename: Vienna
authors.initials: V
authors.lastname: Ludovini
authors.forename: Guido
authors.initials: G
authors.lastname: Bellezza
authors.forename: Anjuta
authors.initials: A
authors.lastname: Pireddu
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Minotti
authors.forename: Chiara
authors.initials: C
authors.lastname: Bennati
authors.forename: Lucio
authors.initials: L
authors.lastname: Crinò
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077547:Crizotinib; D018450:Disease Progression; D004334:Drug Administration Schedule; D066246:ErbB Receptors / Q000187:drug effects / Q000235:genetics*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D058990:Molecular Targeted Therapy / Q000379:methods*; D009154:Mutation / Q000187:drug effects; D015514:Oncogene Proteins, Fusion / Q000187:drug effects / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D011720:Pyrazoles / Q000008:administration & dosage; D011725:Pyridines / Q000008:administration & dosage; D011799:Quinazolines / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: C522504:EML4-ALK fusion protein, human; D015514:Oncogene Proteins, Fusion; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D011799:Quinazolines; D000077547:Crizotinib; C512478:EGFR protein, human; D066246:ErbB Receptors; D000077156:Gefitinib